Elemene-containing hyperthermic intraperitoneal chemotherapy combined with chemotherapy for elderly patients with peritoneal metastatic advanced gastric cancer

Table 1 Clinical characteristics of patients with gastric cancer

Clinical parameters	Group L	Group M	P value
Gender			0.531
Male	14	9
Female	8	8
Age group (yr)			0.748
65-69	11	10
70-75	11	7
ECOG score			0.561
0	14	8
1	5	5
2	3	4
Tumor location			0.667
Proximal	2	3
Middle	4	2
Distal	16	12
Tumor stage			0.192
cT3	12	5
cT4a	9	9
cT4b	1	3
PCI scores			0.508
< 20	15	9
≥ 20	7	8
Abdominal infection (cases)	2	0	0.495
pulmonary infection (cases)	1	1	1.000
Urinary tract infection (cases)	0	1	0.436
Myelosuppression system (grade 3/4, cases)	6	0	0.027
Blood transfusion therapy (cases)	4	0	0.118
Average length of stay (d)	18.7	16.1	0.045

PCI: Peritoneal cancer index; ECOG: Eastern Cooperative Oncology group.

Table 2 Univariate and multivariate analysis of prognostic factors of gastric cancer patients

Clinical parameters	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Gender (male vs female)	0.858 (0.424-1.734)	0.670
Age (< 70 vs ≥ 70)	1.139 (0.564-2.301)	0.717
Group (L vs M)	1.467 (0.714-3.016)	0.297
T stage (T3 vsT4 or above)	2.403 (1.118-5.163)	0.025	1.457 (0.554-3.832)	0.445
Tumor marker (normal vs high)	1.009 (0.473-2.153)	0.981
CD4/CD8 (< 1 vs ≥ 1)	2.505 (1.147-5.467)	0.021	2.051 (0.8534.933)	0.109
Myelosuppression (1/2 vs 3/4)	3.570 (1.291-9.874)	0.014	3.220 (0.985-10.530)	0.053
Times of chemotherapy after HIPEC (< 6 vs ≥ 6)	0.143 (0.060-0.343)	0.000	0.210 (0.070-0.634)	0.006
PCI (< 20 vs ≥ 20)	2.444 (1.105-5.404)	0.027	1.247 (0.417-3.725)	0.693
Ascites (exist1 vs none)	4.106 (1.746-9.658)	0.001	3.084 (0.948-10.027)	0.061

¹Discernible malignant ascites in surgery.